Lead sponsor
Eisai Korea Inc.
5 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
5
Trials led
0
Ongoing
2,755
Total enrollment
37
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
4
Not applicable
1
Trials by status
Completed
4
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's DiseaseAlzheimer's diseasePh 4Completed199
Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD PatientsAlzheimer's diseasePh 4Terminated40